Date: 2011-09-06
Type of information: Grant
Company: Theralpha (France)
Investors: Eurobiomed cluster as part of the 12th FUI (Fond Unique Interministeriel) (France) - Conseil Général 06 (France) - Région PACA (France) - Communauté du Pays d\'Aix en Provence (France) - Clermont Communauté (France)
Amount: €2.55 million
Funding type: grant
Planned used: The grant will finance SulAlgic, a three years program for the preclinical and clinical development of Theralpha’s candidate drug THA903. SubAlgic Consortium includes Synprosis, an Aix en Provence based company specialist in peptide synthesis, formulation and optimization, the Institute of Molecular and Cellular Pharmacology (IPMC, Sophia Antipolis), a worldwide renowned center in neurosciences and the Clermont Ferrand Center of Clinical Investigation, a European leader in pain clinical trials.
Others: The SubAlgic program aims to develop a new drug (THA903) which does not interact with opioid receptors and which can be administered sublingually for acute pain management, an important unmet medical need. THA903 is a small peptide composed of 11 natural amino acids derived from a toxin of king cobra venom (Ophiophagus hannah) that has already shown promising efficacy and tolerability in pre-clinical pain models through sublingual delivery. SubAlgic program includes pre-clinical development completion and a first in human clinical study. This should validate the use of a sublingual form of THA903, for the management of acute pain.
Therapeutic area: CNS diseases
